Tildrakizumab efficacy by metabolic syndrome status in psoriasis: Post hoc analysis of 3-year data from the phase 3 reSURFACE 1 study

被引：0
|
作者：
Lebwohl, Mark G. [1 ]
Gottlieb, Alice B. [2 ]
Mendelsohn, Alan M. [3 ]
Parno, Jeff [3 ]
Rozzo, Stephen J. [4 ]
Menter, Martin [5 ]
机构：
[1] Mt Sinai Hosp, Dept Dermatol, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Sun Pharmaceut, Mumbai, Maharashtra, India
[4] Sun Pharmaceut Ind, Mumbai, Maharashtra, India
[5] Baylor Scott & White, Dallas, TX USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
15938
引用
收藏
页码：AB51 / AB51
页数：1
相关论文
共 50 条
  • [41] TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND METABOLIC SYNDROME: A POST-HOC ANALYSIS OF PHASE 3 STUDIES
    Ritchlin, C.
    Giles, J.
    Ogdie, A.
    Gomez-Reino, J.
    Stockert, L.
    Young, P.
    Wang, C.
    Romero, A. B.
    Kudlacz, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1023 - 1023
  • [42] POST HOC ANALYSIS OF ANTIANEMIC AGENT USE OVER 1 YEAR IN A PHASE 3 STUDY OF SUCROFERRIC OXYHYDROXIDE
    Sprague, S. M.
    Covic, A.
    Floege, J.
    Ketteler, M.
    Spinowitz, B.
    Rakov, V.
    Botha, J.
    Rastogi, A.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 65 (04) : A80 - A80
  • [43] Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study
    Norito Katoh
    Masanori Ikeda
    Yukihiro Ohya
    Hiroyuki Murota
    Xiaofei Hu
    John Liu
    Hayato Niiyama
    Takuya Sasaki
    Eliza M. Raymundo
    Hidehisa Saeki
    Dermatology and Therapy, 2024, 14 : 213 - 232
  • [44] Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study
    Katoh, Norito
    Ikeda, Masanori
    Ohya, Yukihiro
    Murota, Hiroyuki
    Hu, Xiaofei
    Liu, John
    Niiyama, Hayato
    Sasaki, Takuya
    Raymundo, Eliza M.
    Saeki, Hidehisa
    DERMATOLOGY AND THERAPY, 2024, 14 (01) : 213 - 232
  • [45] Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
    Warren, R. B.
    Carrascosa, J. M.
    Fumero, E.
    Schoenenberger, A.
    Lebwohl, M. G.
    Szepietowski, J. C.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (04) : 919 - 927
  • [46] Impact of Concomitant Medication on Efficacy of Telotristat Ethyl - A Post Hoc Subgroup Analysis of the Phase 3 TELESTAR Study in Carcinoid Syndrome
    Anthony, L.
    Kulke, M. H.
    Hoersch, D.
    Bergsland, E.
    Oberg, K.
    Welin, S.
    Lombard-Bohas, C.
    Kunz, P.
    Valle, J. W.
    Kassler-Taub, K.
    Fleming, R.
    Pavel, M.
    NEUROENDOCRINOLOGY, 2017, 105 : 212 - 212
  • [47] Does the Effect of a 3-Year Lifestyle Intervention on Body Weight and Cardiometabolic Health Differ by Prediabetes Metabolic Phenotype? A Post Hoc Analysis of the PREVIEW Study
    Zhu, Ruixin
    Jalo, Elli
    Silvestre, Marta P.
    Poppitt, Sally D.
    Handjieva-Darlenska, Teodora
    Handjiev, Svetoslav
    Huttunen-Lenz, Maija
    Mackintosh, Kelly
    Stratton, Gareth
    Navas-Carretero, Santiago
    Pietilainen, Kirsi H.
    Simpson, Elizabeth
    Macdonald, Ian A.
    Muirhead, Roslyn
    Brand-Miller, Jennie
    Fogelholm, Mikael
    Faerch, Kristine
    Martinez, J. Alfredo
    Westerterp-Plantenga, Margriet S.
    Adam, Tanja C.
    Raben, Anne
    DIABETES CARE, 2022, 45 (11) : 2698 - 2708
  • [48] POST HOC ANALYSIS OF IV IRON AND ESA USE OVER 1 YEAR IN A PHASE 3 STUDY OF SUCROFERRIC OXYHYDROXIDE
    Covic, Adrian
    Sprague, Stuart
    Ketteler, Markus
    Spinowitz, Bruce
    Rastogi, Anjay
    Rakov, Viatcheslav
    Botha, Jaco
    Floege, Juergen
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [49] The application of Dermatology Life Quality Index-Relevant (DLQI-R) in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab: post hoc analysis from the reSURFACE 2 phase III trial
    Laws, P.
    Gaarn Du Jardin, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E41 - E42
  • [50] Bimekizumab for the treatment of moderate to severe psoriasis of the scalp: Post hoc analysis from the BE SURE phase 3 trial
    Reich, Kristian
    Merola, Joseph F.
    Elewski, Boni
    Papp, Kim A.
    Puig, Luis
    Rich, Pheobe
    Cioffi, Christopher
    Cullen, Eva
    Peterson, Luke
    Gottlieb, Alice B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB70 - AB70
12345